Cargando…
Relationships between advanced glycation end products (AGEs), vasoactive substances, and vascular function
Vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) are major cell types that control vascular function, and hence dysfunction of these cells plays a key role in the development and progression of vasculopathies. Abnormal vascular responsiveness to vasoactive substances including vasoco...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Society of Smooth Muscle Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795595/ https://www.ncbi.nlm.nih.gov/pubmed/35095032 http://dx.doi.org/10.1540/jsmr.57.94 |
_version_ | 1784641103555723264 |
---|---|
author | Matsumoto, Takayuki Taguchi, Kumiko Kobayashi, Tsuneo |
author_facet | Matsumoto, Takayuki Taguchi, Kumiko Kobayashi, Tsuneo |
author_sort | Matsumoto, Takayuki |
collection | PubMed |
description | Vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) are major cell types that control vascular function, and hence dysfunction of these cells plays a key role in the development and progression of vasculopathies. Abnormal vascular responsiveness to vasoactive substances including vasoconstrictors and vasodilators has been observed in various arteries in diseases including diabetes, hypertension, chronic kidney diseases, and atherosclerosis. Several substances derived from ECs tightly control vascular function, such as endothelium-derived relaxing and contracting factors, and it is known that abnormal vascular signaling of these endothelium-derived substances is often observed in various diseases. Derangement of signaling in VSMCs and altered function influence vascular reactivity to vasoactive substances and tone, which are important determinants of vascular resistance and blood pressure. However, understanding the molecular mechanisms underlying abnormalities of vascular functions in pathological states is difficult because multiple substances interact in the development of these processes. Advanced glycation end products (AGEs), a heterogeneous group of bioactive compounds, are thought to contribute to vascular dysfunction, which in turn cause the development of several diseases including diabetes, hypertension, stroke, and atherosclerosis. A growing body of evidence suggests that AGEs could affect these cells and modulate vascular function. This study is focused on the link between AGEs and functions of ECs and VSMCs, particularly the modulative effects of AGEs on vascular reactivities to vasoactive substances. |
format | Online Article Text |
id | pubmed-8795595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japan Society of Smooth Muscle Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-87955952022-02-03 Relationships between advanced glycation end products (AGEs), vasoactive substances, and vascular function Matsumoto, Takayuki Taguchi, Kumiko Kobayashi, Tsuneo J Smooth Muscle Res Invited Review Vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) are major cell types that control vascular function, and hence dysfunction of these cells plays a key role in the development and progression of vasculopathies. Abnormal vascular responsiveness to vasoactive substances including vasoconstrictors and vasodilators has been observed in various arteries in diseases including diabetes, hypertension, chronic kidney diseases, and atherosclerosis. Several substances derived from ECs tightly control vascular function, such as endothelium-derived relaxing and contracting factors, and it is known that abnormal vascular signaling of these endothelium-derived substances is often observed in various diseases. Derangement of signaling in VSMCs and altered function influence vascular reactivity to vasoactive substances and tone, which are important determinants of vascular resistance and blood pressure. However, understanding the molecular mechanisms underlying abnormalities of vascular functions in pathological states is difficult because multiple substances interact in the development of these processes. Advanced glycation end products (AGEs), a heterogeneous group of bioactive compounds, are thought to contribute to vascular dysfunction, which in turn cause the development of several diseases including diabetes, hypertension, stroke, and atherosclerosis. A growing body of evidence suggests that AGEs could affect these cells and modulate vascular function. This study is focused on the link between AGEs and functions of ECs and VSMCs, particularly the modulative effects of AGEs on vascular reactivities to vasoactive substances. Japan Society of Smooth Muscle Research 2022-01-29 2021 /pmc/articles/PMC8795595/ /pubmed/35095032 http://dx.doi.org/10.1540/jsmr.57.94 Text en ©2021 The Japan Society of Smooth Muscle Research https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Invited Review Matsumoto, Takayuki Taguchi, Kumiko Kobayashi, Tsuneo Relationships between advanced glycation end products (AGEs), vasoactive substances, and vascular function |
title | Relationships between advanced glycation end products (AGEs), vasoactive
substances, and vascular function |
title_full | Relationships between advanced glycation end products (AGEs), vasoactive
substances, and vascular function |
title_fullStr | Relationships between advanced glycation end products (AGEs), vasoactive
substances, and vascular function |
title_full_unstemmed | Relationships between advanced glycation end products (AGEs), vasoactive
substances, and vascular function |
title_short | Relationships between advanced glycation end products (AGEs), vasoactive
substances, and vascular function |
title_sort | relationships between advanced glycation end products (ages), vasoactive
substances, and vascular function |
topic | Invited Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795595/ https://www.ncbi.nlm.nih.gov/pubmed/35095032 http://dx.doi.org/10.1540/jsmr.57.94 |
work_keys_str_mv | AT matsumototakayuki relationshipsbetweenadvancedglycationendproductsagesvasoactivesubstancesandvascularfunction AT taguchikumiko relationshipsbetweenadvancedglycationendproductsagesvasoactivesubstancesandvascularfunction AT kobayashitsuneo relationshipsbetweenadvancedglycationendproductsagesvasoactivesubstancesandvascularfunction |